JP2014530829A - フコシル化抗体の分離法 - Google Patents
フコシル化抗体の分離法 Download PDFInfo
- Publication number
- JP2014530829A JP2014530829A JP2014536198A JP2014536198A JP2014530829A JP 2014530829 A JP2014530829 A JP 2014530829A JP 2014536198 A JP2014536198 A JP 2014536198A JP 2014536198 A JP2014536198 A JP 2014536198A JP 2014530829 A JP2014530829 A JP 2014530829A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antibodies
- receptor
- fucosylated
- fcγriiia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000926 separation method Methods 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 71
- 108010087819 Fc receptors Proteins 0.000 claims abstract description 57
- 102000009109 Fc receptors Human genes 0.000 claims abstract description 57
- 230000033581 fucosylation Effects 0.000 claims abstract description 42
- 230000027455 binding Effects 0.000 claims abstract description 26
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 58
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 56
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 238000004587 chromatography analysis Methods 0.000 claims description 43
- 150000002482 oligosaccharides Chemical class 0.000 claims description 33
- 229920001542 oligosaccharide Polymers 0.000 claims description 29
- 239000007853 buffer solution Substances 0.000 claims description 25
- 238000010828 elution Methods 0.000 claims description 18
- 239000011159 matrix material Substances 0.000 claims description 16
- 238000004458 analytical method Methods 0.000 claims description 13
- 229920000642 polymer Polymers 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 101710120037 Toxin CcdB Proteins 0.000 claims description 6
- 108010073807 IgG Receptors Proteins 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 102000009490 IgG Receptors Human genes 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 48
- 235000018102 proteins Nutrition 0.000 description 44
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 32
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 31
- 239000007983 Tris buffer Substances 0.000 description 30
- 239000011780 sodium chloride Substances 0.000 description 24
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 21
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 21
- 150000001720 carbohydrates Chemical group 0.000 description 20
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 20
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 18
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- 235000014633 carbohydrates Nutrition 0.000 description 18
- 235000000346 sugar Nutrition 0.000 description 17
- 108060003951 Immunoglobulin Proteins 0.000 description 15
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 102000018358 immunoglobulin Human genes 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 238000001042 affinity chromatography Methods 0.000 description 14
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 13
- 239000011324 bead Substances 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000013595 glycosylation Effects 0.000 description 11
- 238000006206 glycosylation reaction Methods 0.000 description 11
- 239000007993 MOPS buffer Substances 0.000 description 10
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 10
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 10
- 229950006780 n-acetylglucosamine Drugs 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 238000001542 size-exclusion chromatography Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000004471 Glycine Substances 0.000 description 9
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 9
- 150000004676 glycans Chemical group 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 9
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 230000005945 translocation Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000001509 sodium citrate Substances 0.000 description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 7
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 6
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- 108090000087 Carboxypeptidase B Proteins 0.000 description 4
- 102000003670 Carboxypeptidase B Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 101001059701 Spodoptera frugiperda Alpha-mannosidase 2 Proteins 0.000 description 3
- 239000012505 Superdex™ Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000012642 immune effector Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 229960002378 oftasceine Drugs 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- NTBYIQWZAVDRHA-KCDKBNATSA-N (2s,3s,4r,5s)-2-amino-3,4,5-trihydroxyhexanal Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](N)C=O NTBYIQWZAVDRHA-KCDKBNATSA-N 0.000 description 2
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 2
- 101710146120 Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 2
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010019236 Fucosyltransferases Proteins 0.000 description 2
- 102000006471 Fucosyltransferases Human genes 0.000 description 2
- 108700023372 Glycosyltransferases Proteins 0.000 description 2
- 102000051366 Glycosyltransferases Human genes 0.000 description 2
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108010054377 Mannosidases Proteins 0.000 description 2
- 102000001696 Mannosidases Human genes 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 108010083819 mannosyl-oligosaccharide 1,3 - 1,6-alpha-mannosidase Proteins 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010041181 Aleuria aurantia lectin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000012435 analytical chromatography Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SFZBBUSDVJSDGR-XWFYHZIMSA-N beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@H]2[C@H]([C@@H](CO)O[C@@H](O)[C@@H]2O)O)[C@@H]1NC(C)=O SFZBBUSDVJSDGR-XWFYHZIMSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002118 epoxides Chemical group 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 150000008146 mannosides Chemical class 0.000 description 1
- 108010009689 mannosyl-oligosaccharide 1,2-alpha-mannosidase Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108010002529 plasminase B Proteins 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
本発明は、抗体、具体的には、異なる程度のフコシル化を有する抗体の分離の方法に関する。方法は、Fc受容体に対する抗体の結合親和性に基づく。本発明は、異なる程度のフコシル化を有する抗体の分離のためのFc受容体の使用にさらに関する。
ヒトIgG1は、抗原認識を担う可変領域を含む2個のFab(fragment antigen binding)断片と、免疫系の成分と相互作用し、抗体依存性細胞傷害(ADCC)および補体依存性細胞傷害(CDC)のような免疫エフェクター機能を媒介する1個の定常Fc(fragment crystallizable)ドメインとからなる。定常領域のCH2ドメイン内のアスパラギン297(Asn297、N297)にある保存されたNグリコシル化部位に付着した炭水化物構造は、これらのエフェクター機能を媒介するために必須である(1〜4)。
本発明は、FcRγIIIaのようなある種のFc受容体の、フコシル化抗体と(部分または完全)非フコシル化抗体とを区別する能力に基づく分離法を提供する。本法は、分析用および調製用の抗体プールから、異なってフコシル化された抗体を分離するため、固定化されたFc受容体を使用する。本明細書に記載された方法は、抗体プールの炭水化物組成を特徴決定するため、分析的に適用され得る。本方法は、大きな試料数のスクリーニングを可能にするため、例えば、非フコシル化オリゴ糖の高い含量を有する糖鎖改変型抗体を産生する宿主細胞クローンを選択するために使用され得る。調製的適用は、完全非フコシル化抗体集団または完全フコシル化抗体集団を調製し、それらの異なるFcγRIIIa結合特性および生物学的活性を特徴決定することを可能にする。
(a)抗体の集団を提供する工程、
(b)抗体の集団を支持体上に固定化されたFc受容体と接触させる工程、
(c)Fc受容体に特異的に結合していない抗体を溶出させる工程、および
(d)Fc受容体に特異的に結合した抗体を溶出させる工程。
(c1)支持体を洗浄する工程
をさらに含む。
(e)工程(c)および/または工程(d)の溶出された抗体を収集する工程をさらに含む。
(f)収集された抗体を実験用および治療用に使用する工程をさらに含む。
可溶性ヒトFcγRIIIa(V158)K6H6の作製および精製
リン酸カルシウムトランスフェクションを使用して、哺乳動物発現ベクターによりHEK293-EBNA細胞をトランスフェクトすることにより、C末端(リジン)6タグおよび(ヒスチジン)6タグを有する可溶性ヒトFcγRIIIa(V158)(SEQ ID NO 1および2を参照のこと)を作製した。
抗体フコシル化の分析
ヒトIgGからのFc断片の生成。抗体を、1mg当たり0.42Uプラスミン(Roche,Switzerland)を含む50mMトリス(pH8.0)、150mM NaClにおいて、25℃で、72時間インキュベートした。切断されたFc断片を、プロテインAビーズ(GE Healthcare)を使用してFab断片から分離し、50mMトリス(pH8.0)、100mMグリシン、150mM NaClにより洗浄した。Fc断片を、50mMトリス(pH3.0)、100mMグリシン、150mM NaClにより溶出させた。溶出液を、1:40v/v 2Mトリス(pH8.0)を添加することにより中和し、サイズ排除クロマトグラフィカラム(Superdex S200 10/300 GL,GE Healthcare)にロードした。試料を濃縮し、緩衝液を20mMトリス(pH8)(Amicon,Millipore)に交換した。
分析用FcγRIIIaクロマトグラフィ
アフィニティマトリックスの調製。10mgのFcγRIIIa(V158)を、遠心濾過装置(Amicon Ultra MWCO 10kD;Millipore,USA)を使用して、0.1Mリン酸ナトリウム、0.05%(w/v)NaN3(pH7)へ緩衝液交換し、1.2mlの最終容量に濃縮した。タンパク質濃度を、280nmにおける光学濃度を測定するUV分光法により決定し、8mg/mlに調整した。0.14gの乾燥ビーズに相当する440μlのPOROS ALビーズ(Applied Biosystems,USA)を、タンパク質溶液に添加した。その後、41.5μlの0.01M NaOH中の1M NaCNBH3を室温で添加し、懸濁物を終夜インキュベートした。ビーズの遠心分離により上清を除去し、未結合のタンパク質をUV分光法により定量化した。ビーズを、室温で30分間、500μlの1Mトリス(pH7.4)および23μlの0.01M NaOH中の1M NaCNBH3により消光した。ビーズを、1M NaClにより4回、2mM MOPS、150mM NaCl、0.02%(w/v)NaN3(pH7.3)により3回、洗浄した。最後に、POROS ALビーズ1g当たり14mgのFcγRIIIa(V158)をカップリングした。
調製用FcγRIIIaクロマトグラフィ
アフィニティマトリックスの調製。30mgのFcγRIIIa(V158)を、NHSにより活性化されたSepharose 4FF(GE Healthcare,Sweden)とカップリングした。簡単に説明すると、FcγRIIIa(V158)を0.2M NaHCO3、0.5M NaCl(pH8.2)へ交換し、2mlの最終容量に濃縮し、事前に1mM冷HClにより洗浄された3mlのNHSにより活性化されたビーズと共に室温で4時間インキュベートした。上清を除去し、ビーズを、室温で2時間、0.1Mトリス(pH8.5)と共にさらにインキュベートした。次いで、ビーズを、重力流により、空のTricorn 5/150カラム(GE Healthcare,Sweden)に充填した後、1.2ml/分でAkta Explorer 10(GE Healthcare,Sweden)を使用して充填した。14cmのカラム長で、最終カラム体積は2.7mlであった。30mgのヒトFcγRIIIa(V158)を固定化した。
分離された抗体の分析
炭水化物組成の分析。オリゴ糖のMALDI TOF MS分析のため、オリゴ糖を、PNGase FおよびEndo Hにより精製された抗体から切断した(16)。FcγRIIIa(V158)クロマトグラフィによって、非フコシル化グリカンの異なる含量を有する抗体の画分を分離した。フロースルーに相当する第一のピークが、最低量の非フコシル化オリゴ糖を有し、ピーク2および3がそれに続いた(表2および3を参照のこと)。しかしながら、MALDI TOF MS分析は、調製物中の非フコシル化オリゴ糖の全体量のみを明らかにする。
* それぞれのピークに溶出した全てのグリカンのうちのフコース残基を欠くグリカンの百分率。
+ MALDI TOF結果およびESI-MS結果の比較のために計算された値。値は、3種の全てのFcグリコフォームについてのフコースを欠くグリカンの百分率を合計することにより計算される。例えば、ピーク2においては、22/100のFc断片が、2個の非フコシル化グリカンを含み(即ち、44/200のグリカンが非フコシル化であり)、64/100のFc断片が1個の非フコシル化グリカンを含み(即ち、64/200のグリカンが非フコシル化であり)、14/100のFc断片が非フコシル化グリカンを含まず(即ち、0/200のグリカンが非フコシル化であり)、計44+64+0=108/200、=54%の非フコシル化グリカンが、ピーク2に溶出した。
* それぞれのピークに溶出した全てのグリカンのうちのフコース残基を欠くグリカンの百分率。
+ MALDI TOF結果およびESI-MS結果の比較のために計算された値。値は、3種の全てのFcグリコフォームについてのフコースを欠くグリカンの百分率を合計することにより計算される。例えば、ピーク2においては、20.5/100のFc断片が、2個の非フコシル化グリカンを含み(即ち、41/200のグリカンが非フコシル化であり)、68.5/100のFc断片が1個の非フコシル化のグリカンを含み(即ち、68.5/200のグリカンが非フコシル化であり)、11/100のFc断片が非フコシル化グリカンを含まず(即ち、0/200のグリカンが非フコシル化であり)、計41+68.5+0=109.5/200、=54.8%の非フコシル化グリカンが、ピーク2に溶出した。
Claims (26)
- 以下の工程を含む、異なる程度のフコシル化を有する抗体の分離の方法:
(a)抗体の集団を提供する工程、
(b)該抗体の集団を支持体上に固定化されたFc受容体と接触させる工程、
(c)Fc受容体に特異的に結合していない抗体を溶出させる工程、および
(d)Fc受容体に特異的に結合した抗体を溶出させる工程。 - 抗体に対するFc受容体の結合親和性が抗体のフコシル化の程度に依存する、請求項1記載の方法。
- Fc受容体がFcγ受容体である、請求項1または2記載の方法。
- Fc受容体がFcγRIIIaである、前記請求項のいずれか一項記載の方法。
- Fc受容体がFcγRIIIa(V158)である、前記請求項のいずれか一項記載の方法。
- 抗体がIgG抗体である、前記請求項のいずれか一項記載の方法。
- 抗体が、対応する非糖鎖改変型抗体と比較して、増加した割合の非フコシル化オリゴ糖をそのFc領域に有するよう糖鎖改変されている、前記請求項のいずれか一項記載の方法。
- 抗体の集団が、精製されている、前記請求項のいずれか一項記載の方法。
- 抗体の集団が、プロテインAまたはプロテインGを使用してアフィニティ精製されている、前記請求項のいずれか一項記載の方法。
- 支持体がポリマーマトリックスである、前記請求項のいずれか一項記載の方法。
- 支持体がクロマトグラフィカラムに含まれている、前記請求項のいずれか一項記載の方法。
- (c1)支持体を洗浄する工程
をさらに含む、前記請求項のいずれか一項記載の方法。 - 工程(c)の溶出が、工程(b)における接触させる工程の後の抗体集団内で遊離のままである抗体の分離を含む、前記請求項のいずれか一項記載の方法。
- 工程(c)において溶出される抗体が完全フコシル化抗体である、前記請求項のいずれか一項記載の方法。
- 工程(d)の溶出が、支持体を、抗体のFc受容体との結合を妨げる緩衝溶液と接触させることを含む、前記請求項のいずれか一項記載の方法。
- 前記緩衝溶液が約3〜約5の範囲のpH値を有する、請求項15記載の方法。
- 工程(d)の溶出が異なるpH値で実施される、前記請求項のいずれか一項記載の方法。
- 前記pH値が4.6および4.2を含む、請求項17記載の方法。
- 工程(d)において溶出される抗体が、部分フコシル化抗体および/または完全非フコシル化抗体である、前記請求項のいずれか一項記載の方法。
- 分析用である、前記請求項のいずれか一項記載の方法。
- 調製用である、前記請求項のいずれか一項記載の方法。
- (e)工程(c)および/または工程(d)の溶出された抗体を収集する工程
をさらに含む、前記請求項のいずれか一項記載の方法。 - (f)収集された抗体を実験用または治療用に使用する工程
をさらに含む、請求項22記載の方法。 - 異なる程度のフコシル化を有する抗体の分離の方法におけるFc受容体の使用。
- 異なる程度のフコシル化を有する抗体の分離の方法において使用するための支持体上に固定化されたFc受容体。
- 上記の発明。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11185798.3 | 2011-10-19 | ||
EP11185798 | 2011-10-19 | ||
PCT/EP2012/070439 WO2013057078A1 (en) | 2011-10-19 | 2012-10-16 | Separation method for fucosylated antibodies |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018113533A Division JP2018184406A (ja) | 2011-10-19 | 2018-06-14 | フコシル化抗体の分離法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014530829A true JP2014530829A (ja) | 2014-11-20 |
JP6356605B2 JP6356605B2 (ja) | 2018-07-11 |
Family
ID=47019025
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014536198A Active JP6356605B2 (ja) | 2011-10-19 | 2012-10-16 | フコシル化抗体の分離法 |
JP2018113533A Pending JP2018184406A (ja) | 2011-10-19 | 2018-06-14 | フコシル化抗体の分離法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018113533A Pending JP2018184406A (ja) | 2011-10-19 | 2018-06-14 | フコシル化抗体の分離法 |
Country Status (12)
Country | Link |
---|---|
US (2) | US9994610B2 (ja) |
EP (1) | EP2768845B1 (ja) |
JP (2) | JP6356605B2 (ja) |
KR (1) | KR20140077178A (ja) |
CN (2) | CN103890002A (ja) |
BR (1) | BR112014009178A2 (ja) |
CA (1) | CA2851053A1 (ja) |
ES (1) | ES2619677T3 (ja) |
HK (2) | HK1258766A1 (ja) |
MX (1) | MX355048B (ja) |
RU (1) | RU2650873C2 (ja) |
WO (1) | WO2013057078A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201516149A (zh) | 2006-09-13 | 2015-05-01 | Abbvie Inc | 細胞培養改良 |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
RU2520838C2 (ru) | 2008-10-20 | 2014-06-27 | Эббви Инк | Выделение и очистка антител с использованием аффинной хроматографии на основе белка а |
CN104974251A (zh) | 2008-10-20 | 2015-10-14 | Abbvie公司 | 在抗体纯化过程中的病毒灭活 |
JP2014527518A (ja) | 2011-07-20 | 2014-10-16 | ゼプテオン インコーポレイテッド | ポリペプチド分離法 |
JP6451119B2 (ja) * | 2014-07-17 | 2019-01-16 | 東ソー株式会社 | 抗体依存性細胞傷害活性の強さに基づき抗体を分離する方法 |
US20180319838A1 (en) | 2015-11-04 | 2018-11-08 | Biogen Ma Inc. | Conjugation methods for modifying or immobilizing proteins |
CA3082019A1 (en) * | 2017-04-06 | 2018-10-11 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
KR20220025873A (ko) * | 2019-07-03 | 2022-03-03 | 메르크 파텐트 게엠베하 | 당형태 정제 |
WO2021010349A1 (ja) * | 2019-07-12 | 2021-01-21 | 国立大学法人北海道大学 | 非アルコール性脂肪肝炎の血中線維化マーカーの開発 |
GB202204016D0 (en) * | 2022-03-22 | 2022-05-04 | Ucl Business Plc | Affinity chromatography ligands for antibody glycovariant separation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01502875A (ja) * | 1987-03-18 | 1989-10-05 | エス・ビィ・2・インコーポレイテッド | 変性抗体のまたは変性抗体に関する改良 |
JPH11501522A (ja) * | 1995-06-07 | 1999-02-09 | メダレツクス・インコーポレーテツド | 抗Fcレセプター抗体を含んでなる治療化合物 |
JP2008543868A (ja) * | 2005-06-17 | 2008-12-04 | ワイス | Fc領域含有タンパク質を精製する方法 |
WO2010048313A2 (en) * | 2008-10-22 | 2010-04-29 | Biogen Idec Ma Inc. | Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins |
JP2011105716A (ja) * | 1998-12-03 | 2011-06-02 | Max-Planck-Ges Zur Foerderung Der Wissenschaften Ev | 組換え可溶性Fc受容体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
CA2513797C (en) | 2003-01-22 | 2016-05-03 | Glycart Biotechnology Ag | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
RU2412200C2 (ru) * | 2004-11-12 | 2011-02-20 | Ксенкор, Инк. | Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn |
US7699979B2 (en) * | 2005-01-07 | 2010-04-20 | Board Of Trustees Of The University Of Arkansas | Separation system and efficient capture of contaminants using magnetic nanoparticles |
EP2483693B1 (en) | 2009-10-02 | 2014-12-03 | Roche Glycart AG | A-fucosylation detection in antibodies |
JP2014527518A (ja) * | 2011-07-20 | 2014-10-16 | ゼプテオン インコーポレイテッド | ポリペプチド分離法 |
-
2012
- 2012-10-16 EP EP12772787.3A patent/EP2768845B1/en active Active
- 2012-10-16 RU RU2014118552A patent/RU2650873C2/ru active
- 2012-10-16 US US14/352,411 patent/US9994610B2/en active Active
- 2012-10-16 WO PCT/EP2012/070439 patent/WO2013057078A1/en active Application Filing
- 2012-10-16 CN CN201280051644.2A patent/CN103890002A/zh active Pending
- 2012-10-16 KR KR1020147010510A patent/KR20140077178A/ko active IP Right Grant
- 2012-10-16 MX MX2014004604A patent/MX355048B/es active IP Right Grant
- 2012-10-16 JP JP2014536198A patent/JP6356605B2/ja active Active
- 2012-10-16 CN CN201810181408.1A patent/CN108314729A/zh active Pending
- 2012-10-16 BR BR112014009178A patent/BR112014009178A2/pt not_active Application Discontinuation
- 2012-10-16 ES ES12772787.3T patent/ES2619677T3/es active Active
- 2012-10-16 CA CA2851053A patent/CA2851053A1/en not_active Abandoned
-
2014
- 2014-12-23 HK HK19101095.1A patent/HK1258766A1/zh unknown
- 2014-12-23 HK HK14112853.5A patent/HK1199272A1/xx unknown
-
2018
- 2018-05-29 US US15/991,853 patent/US20180265544A1/en not_active Abandoned
- 2018-06-14 JP JP2018113533A patent/JP2018184406A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01502875A (ja) * | 1987-03-18 | 1989-10-05 | エス・ビィ・2・インコーポレイテッド | 変性抗体のまたは変性抗体に関する改良 |
JPH11501522A (ja) * | 1995-06-07 | 1999-02-09 | メダレツクス・インコーポレーテツド | 抗Fcレセプター抗体を含んでなる治療化合物 |
JP2011105716A (ja) * | 1998-12-03 | 2011-06-02 | Max-Planck-Ges Zur Foerderung Der Wissenschaften Ev | 組換え可溶性Fc受容体 |
JP2008543868A (ja) * | 2005-06-17 | 2008-12-04 | ワイス | Fc領域含有タンパク質を精製する方法 |
WO2010048313A2 (en) * | 2008-10-22 | 2010-04-29 | Biogen Idec Ma Inc. | Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins |
Non-Patent Citations (6)
Title |
---|
BIOL. PHARM. BULL. (2009) VOL.32, NO.9, PP.1604-1608, JPN6016029890, ISSN: 0003597095 * |
CLINCAL CANCER RESEARCH (2004) VOL.10, PP.6248-6255, JPN6016029887, ISSN: 0003597094 * |
J. BIOL. CHEM. (2002) VOL.277, NO.30, PP.26733-26740, JPN6016029894, ISSN: 0003597096 * |
J. BIOL. CHEM. (2003) VOL.278, NO.5, PP.3466-3473, JPN6016029884, ISSN: 0003597099 * |
J. MOL. BIOL. (2004) VOL.336, PP.1239-1249, JPN6016029883, ISSN: 0003597098 * |
JOURNAL OF IMMUNOLOGICAL METHODS (1989) VOL.124, PP.131-135, JPN6016029881, ISSN: 0003597097 * |
Also Published As
Publication number | Publication date |
---|---|
ES2619677T3 (es) | 2017-06-26 |
CN108314729A (zh) | 2018-07-24 |
BR112014009178A2 (pt) | 2018-09-04 |
JP2018184406A (ja) | 2018-11-22 |
EP2768845A1 (en) | 2014-08-27 |
CN103890002A (zh) | 2014-06-25 |
HK1258766A1 (zh) | 2019-11-22 |
US20140255399A1 (en) | 2014-09-11 |
US20180265544A1 (en) | 2018-09-20 |
WO2013057078A1 (en) | 2013-04-25 |
EP2768845B1 (en) | 2017-01-18 |
KR20140077178A (ko) | 2014-06-23 |
RU2650873C2 (ru) | 2018-04-17 |
CA2851053A1 (en) | 2013-04-25 |
RU2014118552A (ru) | 2015-11-27 |
US9994610B2 (en) | 2018-06-12 |
MX2014004604A (es) | 2014-05-27 |
JP6356605B2 (ja) | 2018-07-11 |
HK1199272A1 (en) | 2015-06-26 |
MX355048B (es) | 2018-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6356605B2 (ja) | フコシル化抗体の分離法 | |
EP2814587B1 (en) | Fc-receptor based affinity chromatography | |
CN106103478B (zh) | 抗体体内半寿期的体外预测 | |
KR20160044023A (ko) | 히드록시아파타이트 크로마토그래피를 사용하는 이중특이적 항체 및 이중특이적 항체 생산 부산물의 분리 | |
CN105163758B (zh) | 包含富集主要电荷同工型的抗体组合物的药物 | |
EP3048112B1 (en) | Fc-BINDING PROTEIN, METHOD FOR PRODUCING SAID PROTEIN, AND ANTIBODY ADSORBENT USING SAID PROTEIN, AND METHODS FOR PURIFYING AND IDENTIFYING ANTIBODY USING SAID ADSORBENT | |
US20140371427A1 (en) | IgG2 DISULFIDE ISOFORM SEPARATION | |
CN103827134A (zh) | 多肽分离方法 | |
Freimoser–Grundschober et al. | FcγRIIIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodies | |
CN114450292A (zh) | 断裂型内含肽、使用其的重组多肽的制备方法 | |
CA2766839A1 (en) | Enzymatic antibody processing | |
Simonov et al. | Control of therapeutic IgG antibodies galactosylation during cultivation process and its impact on IgG1/FcγR interaction and ADCC activity | |
EP3938398A2 (en) | Non-consensus glycosylation of bispecific antibodies | |
KR102617873B1 (ko) | 티로신 황산화 항체 변이체의 제거를 위한 정제 프로세스, 정제된 조성물 | |
RU2793400C2 (ru) | Способ очистки для удаления вариантов антител с сульфатированием тирозина; очищенные композиции | |
CN114085291B (zh) | 一种降低或消除重组蛋白cex酸性峰的方法 | |
JP2018057387A (ja) | 糖タンパク質の凝集を低下させるための方法 | |
Durocher et al. | Towards the development of a surface plasmon resonance assay to evaluate the glycosylation pattern of monoclonal antibodies using the extracellular domains of CD16a and CD64 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150428 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151009 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160803 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170710 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180109 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180516 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180614 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6356605 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |